Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) have been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $26.25.

A number of brokerages have recently weighed in on TARA. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Tuesday, April 21st. JPMorgan Chase & Co. dropped their target price on Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, May 14th. Wall Street Zen raised Protara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. Finally, Oppenheimer lifted their price target on Protara Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, May 20th.

Institutional Investors Weigh In On Protara Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company lifted its stake in Protara Therapeutics by 22.2% during the first quarter. The Manufacturers Life Insurance Company now owns 13,548 shares of the company’s stock worth $71,000 after purchasing an additional 2,464 shares during the last quarter. Rhumbline Advisers raised its holdings in Protara Therapeutics by 8.2% during the third quarter. Rhumbline Advisers now owns 34,137 shares of the company’s stock worth $148,000 after purchasing an additional 2,596 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Protara Therapeutics by 26.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,736 shares of the company’s stock worth $111,000 after purchasing an additional 4,383 shares in the last quarter. Two Sigma Investments LP lifted its position in shares of Protara Therapeutics by 35.8% during the 3rd quarter. Two Sigma Investments LP now owns 19,558 shares of the company’s stock worth $85,000 after buying an additional 5,154 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Protara Therapeutics by 7.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 102,499 shares of the company’s stock worth $546,000 after buying an additional 6,725 shares during the last quarter. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Stock Up 2.2%

Shares of NASDAQ:TARA opened at $4.20 on Friday. The firm’s 50 day moving average price is $4.47 and its 200 day moving average price is $5.27. The stock has a market cap of $236.04 million, a price-to-earnings ratio of -3.13 and a beta of 1.48. Protara Therapeutics has a fifty-two week low of $2.97 and a fifty-two week high of $7.82.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.05. On average, equities analysts anticipate that Protara Therapeutics will post -1.44 EPS for the current year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.